1. Home
  2. CEVA vs PRTC Comparison

CEVA vs PRTC Comparison

Compare CEVA & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CEVA
  • PRTC
  • Stock Information
  • Founded
  • CEVA 1999
  • PRTC 2015
  • Country
  • CEVA United States
  • PRTC United States
  • Employees
  • CEVA N/A
  • PRTC N/A
  • Industry
  • CEVA Semiconductors
  • PRTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CEVA Technology
  • PRTC Health Care
  • Exchange
  • CEVA Nasdaq
  • PRTC Nasdaq
  • Market Cap
  • CEVA 508.9M
  • PRTC 439.8M
  • IPO Year
  • CEVA 2000
  • PRTC N/A
  • Fundamental
  • Price
  • CEVA $21.97
  • PRTC $17.40
  • Analyst Decision
  • CEVA Strong Buy
  • PRTC Buy
  • Analyst Count
  • CEVA 5
  • PRTC 1
  • Target Price
  • CEVA $35.60
  • PRTC $45.00
  • AVG Volume (30 Days)
  • CEVA 265.4K
  • PRTC 6.0K
  • Earning Date
  • CEVA 08-06-2025
  • PRTC 04-30-2025
  • Dividend Yield
  • CEVA N/A
  • PRTC N/A
  • EPS Growth
  • CEVA N/A
  • PRTC N/A
  • EPS
  • CEVA N/A
  • PRTC 0.21
  • Revenue
  • CEVA $109,112,000.00
  • PRTC $4,828,000.00
  • Revenue This Year
  • CEVA $4.47
  • PRTC $35.98
  • Revenue Next Year
  • CEVA $16.50
  • PRTC $115.38
  • P/E Ratio
  • CEVA N/A
  • PRTC $7.66
  • Revenue Growth
  • CEVA 17.04
  • PRTC 44.98
  • 52 Week Low
  • CEVA $16.02
  • PRTC $13.30
  • 52 Week High
  • CEVA $38.94
  • PRTC $26.79
  • Technical
  • Relative Strength Index (RSI)
  • CEVA 59.64
  • PRTC 48.72
  • Support Level
  • CEVA $20.01
  • PRTC $16.50
  • Resistance Level
  • CEVA $22.63
  • PRTC $18.02
  • Average True Range (ATR)
  • CEVA 0.88
  • PRTC 0.38
  • MACD
  • CEVA 0.35
  • PRTC -0.16
  • Stochastic Oscillator
  • CEVA 94.39
  • PRTC 43.64

About CEVA CEVA Inc.

CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: